30 results about "Pregnane" patented technology

The invention provides a preparation method of pregnanolone, which comprises the following steps: 1) under the action of a first catalyst, progesterone and anhydride react to obtain a compound as shown in a formula (I); 2) under the action of a dehydrating agent and a second catalyst, diol reacts with the compound shown in the formula (I), and a compound shown in a formula (II) is obtained after deprotection; 3) under the action of a ligand and a third catalyst, selectively reducing the compound as shown in the formula (II) by hydrogen to obtain a compound as shown in a formula (III); and 4) reacting the compound as shown in the formula (III) with a reducing agent, and deprotecting to obtain pregnanolone. According to the present invention, progesterone is adopted as the starting material, enol esterification reaction, ketal protection, ester group hydrolysis, hydrogenation and reduction hydrolysis are performed to obtain pregnanolone, the method has characteristics of mild condition, conventional reagent, simple operation and suitableness for industrialization, the obtained product has characteristics of good quality, purity of more than 99.0%, and total yield of about 90.0%.

Provided in the present invention are a 3-hydroxyl-5-pregnane-20-one derivative as shown in formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the derivative or the pharmaceutically acceptable salt thereof. The derivative or the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the above-mentioned derivative or salt of the present invention can be used to prepare a drug for treating a disease caused by abnormalities in the central nervous system.

This invention relates to a cinnabar-2-oxide compound, its preparation method, and its uses. The cinnabar-2-oxide compound is shown in formula (I). By oxidizing a nitrogen atom to an N-oxide and then combining it with a heteroaryl group, the above-mentioned cinnabar-2-oxide compound achieves good α2-GABAA receptor affinity and positive regulatory activity. Simultaneously, it has the potential to significantly reduce PXR (pregnane X receptor) activation, thereby reducing drug-drug interactions and improving drug efficacy or safety.

The invention describes compounds useful for the treatment of viral infection caused by Dengue virus, which comprise compounds that inhibit viral replication of the virus, such as pregnane X receptor (PXR) antagonists, as well as pharmaceutical compositions comprising them, which are useful for the treatment of said viral infection, as well as methods of treatment for viral infection using said compounds and the compositions comprising them.

The present invention provides a crystal of a compound of formula I as a 3-hydroxy-5-pregnane-20-one derivative and a preparation method thereof. Specifically, the invention provides a crystal form G of a compound shown as a formula I and a preparation method thereof. The crystal form G of the present invention has significantly improved solubility, excellent storage stability at various temperatures, and low hygroscopicity, thereby improving druggability, and bringing very excellent effects for production, sales and transportation of drugs.

The present invention relates to a novel process for synthesizing 3α-hydroxy-5α-pregnane-20-one, which is generally known as bryosone, wherein the corresponding cyclic 20-ketal compound or cyclic 20-ketalthiolate compound of formula (IV) is deprotected using iodine in an organic solvent.

The invention relates to the technical field of medicine synthesis, in particular to C3 and C20 N-containing pregnane type steroid alkaloid derivatives as well as a preparation method and application thereof. A pregnane type steroid alkaloid skeleton in Miao medicine tri-silver is used as a template, a steroid compound epiandrosterone is used as a raw material, C3-site and C20-site keto compounds are obtained through Wittig alkylenation reaction and oxidation, and the C3-site and C20-site keto compounds are subjected to continuous reductive amination reaction to obtain a series of pregnane type steroid alkaloid derivatives containing N at C3 site and C20 site simultaneously. The C3 and C20 N-containing pregnane type steroid alkaloid derivatives provided by the invention have remarkable anti-inflammatory and anti-gastric ulcer activity, and a scientific basis is provided for searching novel anti-inflammatory and anti-gastric ulcer lead compounds with high selectivity and safety and developing novel anti-inflammatory and anti-gastric ulcer medicines.

The present invention discloses a steroidal dihydropyrazole thiazoline derivative, 3β-hydroxy-pregnane-5-en-17β-yl-5'-(substituted phenyl)-1'-(4''-phenyl-[1'',3'']-thiazol-2''-yl)-4',5'-dihydropyrazole-3'-yl. The present invention also discloses the use of the steroidal dihydropyrazole thiazoline derivative. The steroidal dihydropyrazole thiazoline derivative of the present invention has a strong inhibitory effect on nitric oxide (NO) production in RAW 264.7 mouse peritoneal macrophages induced by lipopolysaccharide (LPS), especially compound 4 in the prepared steroidal dihydropyrazole thiazoline derivative has an IC of 0.05. 50 The value is better than that of the positive control methylprednisolone, and the toxicity to cells is low. The steroidal derivative containing a dihydropyrazole thiazoline heterocycle provided by the present invention is a new structural compound, which shows higher activity than existing first-line anti-inflammatory drugs.

The present invention relates to a method for preparing 21-(acetyloxy)-17-(1-oxopropoxy)-pregnane-4-ene-3,20-dione (VI) having the following formula: Compound (VI) can be used as a precursor for synthesizing the steroid compound clapriston for treating acne.

The present invention provides a 3-hydroxy-5-pregnan-20-one derivative represented by Formula I or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising the derivative or a pharmaceutically acceptable salt thereof. The derivative or a pharmaceutically acceptable salt thereof of the present invention, or a pharmaceutical composition comprising the derivative or salt thereof, can be used to produce a drug for treating diseases caused by central nervous system abnormalities. [Formula 1] JPEG2022545047000052.jpg4199

A process for preparing and purifying alfaxalone (3α-hydroxy-5α-pregnane) from a crude mixture of 3α- and 3β-hydroxy-5α-pregnane; and subsequent purification of the 17α- and 17β-enantiomers to obtain the 17β- enantiomer (alfaxalone).

This application provides a method for preparing pregnanelonone, comprising the following steps: Step 1) under the action of a first catalyst, progesterone reacts with an acid anhydride to obtain the compound shown in formula (I); Step 2) under the action of a dehydrating agent and a second catalyst, a diol reacts with the compound shown in formula (I), and after deprotection, the compound shown in formula (II) is obtained; Step 3) under the action of a ligand and a third catalyst, the compound shown in formula (II) is selectively reduced by hydrogen to obtain the compound shown in formula (III); Step 4) the compound shown in formula (III) reacts with a reducing agent and is then deprotected to obtain pregnanelonone. This application uses progesterone as the starting material, and obtains pregnanelonone through enol esterification, ketal protection, ester hydrolysis, hydrogenation, and reductive hydrolysis. This method is mild, uses conventional reagents, is simple to operate, suitable for industrialization, and yields a high-quality product with a purity of over 99.0% and an overall yield of approximately 90.0%.

The present invention provides 3-hydroxy-5-pregnane-20-one derivatives of Formula I or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing such derivatives or pharmaceutically acceptable salts. The derivatives or pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing such derivatives or salts, can be used to prepare medicaments for treating diseases caused by central nervous system abnormalities. #imgabs0#

A method for preparing and purifying alfasalone (3α-hydroxy-5α-pregnane) from a crude mixture of 3α- and 3β-hydroxy-5α-pregnane, and subsequently purifying the 17α- and 17β-enantiomers to obtain the 17β-enantiomer (alfasalone).

The present invention discloses a novel alkaloid derivative, its synthesis method and application. Based on the active pregnane-type alkaloid skeleton structure in the Miao medicine "Sanyangyin", using epiandrosterone as a raw material, a series of C20-oxime pregnane-type alkaloid derivatives are obtained through reactions such as Wittig reaction, reduction reaction, Corey oxidation, reductive amination, and N-alkylation. This method has a simple and efficient preparation process and mild reaction conditions. The synthesized C20-oxime pregnane-type alkaloid derivatives have excellent anti-tumor activity and anti-inflammatory properties and can be used in anti-tumor and anti-inflammatory drugs. It provides a scientific basis for the new drug development and application of novel anti-tumor and anti-inflammatory pregnane-type alkaloids.

To provide novel lipid drug conjugates which facilitate stable transport of a pharmaceutical agent to the intestinal lymph and readily revert to a parent drug so as to be active.SOLUTION: Provided is a compound of the following Formula I, wherein A is a therapeutic agent selected from a naturally occurring or non-naturally occurring pregnane neurosteroid, or an analog or prodrug thereof.SELECTED DRAWING: None

The present application relates to the field of medicine, specifically relates to a kind of formula I shown compound, its racemic body, stereoisomer, tautomer, solvate, polymorph or their pharmaceutically acceptable salt:Wherein:R2,R4 respectively independent from H or D;R1,R3 respectively independent from CH3,CH2D,CHD2 Or CD3;Formula I compound contains at least one deuterium atom.The present application is under the premise of retaining allopregnanolone pharmacological activity, by the structure modification of the hydroxyl group of allopregnanolone obtains the allopregnanolone derivative suitable for oral administration, it has good physical / chemical stability.

The aim is to provide plasma biomarkers for bone infections in humans. [Solution] A plasma biomarker for bone infection comprising one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-didihydroxy-5a-pregnane-20-one-2, aldosterone, bisacron-2, naringenin, tauro-α-mulicolic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestic acid, AEA(22:4)-1, AEA(22:4)-2, bilbertin, sphingosine, malic acid, and succinic acid.

Provided herein are compounds that are potent inhibitors of the Mycobacterium tuberculosis (MTB) RNA polymerase (RNAP), which exhibit significantly reduced activation of the human pregnane X receptor (hPXR), resulting in dramatically reduced C induction of hepatic cytochromes P450 2C9 and 3A4 (CYP2C9, CYP3A4), as well as a number of Phase II metabolism enzymes. Also provided herein are pharmaceutical compositions comprising the compounds, and methods of treating tuberculosis using the compounds.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to biphenyl monoacyl compounds or pharmaceutically acceptable salts and application thereof. According to the biphenyl monoacyl compound provided by the invention, the expression of PXR downstream key protein is up-regulated by activating a PXR receptor, and the biphenyl monoacyl compound shows a good treatment effect on liver and other metabolic system diseases. The biphenyl monoacyl compound has a good effect in the aspects of promoting liver regeneration, resisting cholestasis and the like, and has a good development prospect.

The present disclosure in one aspect, relates to compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention further relates to the use of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse drug reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, or an anticonvulsant agent. The invention, in one aspect, further relates to compounds, compositions, and methods for identifying PXR ligands. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention relates to a cinnoline-2-oxide compound as well as a preparation method and application thereof. The cinnoline-2-oxide compound is shown as a formula (I) in the specification. According to the cinnoline-2-oxide compound, a nitrogen atom is oxidized into N-oxide to be matched with heteroaryl, good alpha2-GABAA receptor affinity activity and positive regulation activity can be achieved, meanwhile, the cinnoline-2-oxide compound has the potential of remarkably reducing and activating a PXR (pregnane X receptor), then the drug-drug interaction can be reduced, and the clinical application prospect is broad. The medicine curative effect or safety is improved. # imgabs0 #

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering a 3α-OH-5α-pregnan-20-one containing composition to a subject having a CNS disorder. The composition preferably exhibits a high release rate of the 3α-OH-5α-pregnan-20-one, and when mixed with an aqueous solution, a high dispersion value. The composition is also preferably more soluble than a comparable SBE-β-CD containing composition. Further in the embodiment, the solubility of the composition when mixed in a FeSSIF is substantially similar to the solubility of the composition when mixed in a FaSSIF.

The present disclosure relates to 1,4,5-substituted 1,2,3-triazoles useful as modulators of pregnane X receptor (PXR) and in the treatment of disorders associated with PXR dysfunction (e.g., disorders of uncontrolled cellular proliferation, bowel disorders). The invention further relates to uses of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, and an anticonvulsant agent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure relates to 1,4,5-substituted 1,2,3-triazoles useful as modulators of pregnane X receptor (PXR) and in the treatment of disorders associated with PXR dysfunction (e.g., disorders of uncontrolled cellular proliferation, bowel disorders). The invention further relates to uses of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, and an anticonvulsant agent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses a C20 keto-pregnane alkaloid derivative and a synthesis method and application thereof. The invention is based on the skeleton structure of active pregnane alkaloids in the Miao medicine Sanliangyin, uses epiandrosterone as a raw material, and obtains a series of C20 keto-pregnane alkaloid derivatives through Wittig reaction, reduction reaction, Corey oxidation, reductive amination, N alkylation and other reactions. The raw materials of the method are cheap and easy to obtain, the reaction conditions are mild, the operation is simple, and the reaction yield is good. The synthesized C20 keto-pregnane alkaloid derivative has excellent anti-tumor activity and anti-inflammatory activity, and can be used in anti-liver cancer, anti-colorectal cancer and anti-inflammatory drugs. It provides a scientific basis for the development and application of new drugs for new anti-tumor and anti-inflammatory pregnane alkaloids.

Disclosed are methods and oral compositions for treating CNS disorders. An embodiment of the invention comprises orally administering a 3α-OH-5β-pregnan-20-one containing composition to a subject having a CNS disorder. The composition preferably exhibits a fast release rate of the 3α-OH-5β-pregnan-20-one. The current compositions may provide desired serum levels of 3α-OH-5β-pregnan-20-one to effectively treat CNS disorders. The oral compositions and methods disclosed herein may be administered to a subject in need of CNS disorder therapy, to deliver therapeutically effective amounts of 3α-OH-5β-pregnan-20-one for treating CNS disorders.